The Emerging Role of Yttrium-90 in Primary and Metastatic Liver Cancer
There is no excerpt because this is a protected post.
Iobenguane I-131 FDA approved for rare adrenal neuroendocrine tumours
On July 30, 2018, the FDA approved iobenguane I-131 (Azedra®, Progenics Pharmaceuticals), a radioactive therapeutic agent, for the treatment of adult and paediatric patients ≥12 years with iobenguane scan positive, locally advanced or metastatic pheochromocytoma or paraganglioma (PPGL) not amenable to surgery and indicated for systemic therapy.